Evidence map›Paper›PMID 39189458›Full record

ArticleNucleic acids research2024

ADARp150 counteracts whole genome duplication.

Frank van Gemert, Alexandra Drakaki, Isabel Morales Lozano, Daniël de Groot, Maud Schoot Uiterkamp, Natalie Proost, Cor Lieftink, Marieke van de Ven, Roderick L Beijersbergen, Heinz Jacobs and 1 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Frank van GemertDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Alexandra DrakakiDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Isabel Morales LozanoDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Daniël de GrootDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Maud Schoot UiterkampDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Natalie ProostMouse Clinic for Cancer and Aging Research, Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Cor LieftinkDivision of Molecular Carcinogenesis, NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Marieke van de VenMouse Clinic for Cancer and Aging Research, Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Roderick L BeijersbergenDivision of Molecular Carcinogenesis, NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Heinz JacobsDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0001-6227-9850
Hein Te RieleDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0003-0255-4042

Funding

KWF Kankerbestrijding 11074Netherlands Cancer Institute
6 · The paper itself

Abstract

Impaired control of the G1/S checkpoint allows initiation of DNA replication under non-permissive conditions. Unscheduled S-phase entry is associated with DNA replication stress, demanding for other checkpoints or cellular pathways to maintain proliferation. Here, we uncovered a requirement for ADARp150 to sustain proliferation of G1/S-checkpoint-defective cells under growth-restricting conditions. Besides its well-established mRNA editing function in inversely oriented short interspersed nuclear elements (SINEs), we found ADARp150 to exert a critical function in mitosis. ADARp150 depletion resulted in tetraploidization, impeding cell proliferation in mitogen-deprived conditions. Mechanistically we show that ADAR1 depletion induced aberrant expression of Cyclin B3, which was causative for mitotic failure and whole-genome duplication. Finally, we find that also in vivo ADAR1-depletion-provoked tetraploidization hampers tumor outgrowth.

Indexed as

Adenosine DeaminaseRNA-Binding ProteinsAnimalsCell Line, TumorCell ProliferationDNA ReplicationG1 Phase Cell Cycle CheckpointsGenome, HumanHumansMiceMitosisRNA EditingTetraploidyADAR protein, humanAdenosine DeaminaseRNA-Binding Proteins

Identifiers

PMID39189458
PMCPMC11417406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.